RADIUM FACTS TRIAL
RADIUM FACTS PLUS

And fewer men in the radium-223 group experienced serious adverse events (47 percent versus 60 percent) or stopped treatment because of adverse events (16 percent versus 21 percent) than in the placebo group.Ĭompared with men in the placebo group, men assigned to receive radium-223 also reported a better quality of life as measured using a standard assessment tool. Men assigned to receive radium-223 also lived longer without having a skeletal-related event than men assigned to receive the placebo (a median of 15.6 months versus 9.8 months). An overall survival benefit with radium-223 was seen in all subgroups of men analyzed-for example, men benefited whatever the extent of their disease and regardless of whether they had previously received docetaxel or were currently being treated with bisphosphonates.

Median overall survival was 14.9 months for the men assigned to receive radium-223 and 11.3 months for those assigned to the placebo.

RADIUM FACTS TRIAL

The trial was funded by Bayer Healthcare Pharmaceuticals and Algeta, the company that developed and manufactures radium-223. The results published in the NEJM paper reflect patient outcomes before any crossover took place. In early 2011, when an independent data safety and monitoring committee evaluated interim data from the trial and found that men who were assigned to receive radium-223 had statistically significantly better overall survival than men assigned to receive the placebo, the trial was stopped early and men taking the placebo were allowed to “cross over” and take radium-223. Secondary endpoints included time to the first symptomatic skeletal event-such as a bone fracture, spinal cord compression, or the need for radiation to treat bone-related symptoms-and quality-of-life measures. The trial’s primary endpoint was overall survival.

RADIUM FACTS PLUS

Men in the trial were randomly assigned to receive either radium-223 (six intravenous injections, one every 4 weeks) plus the best standard of care or a placebo plus the best standard of care.

The Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial enrolled 921 patients with metastatic, castration-resistant prostate cancer.

Once the drug, which can be given intravenously, reaches bone, it emits very low levels of radiation that travel less than 100 microns, or approximately four one-thousandths of an inch, limiting damage to the surrounding tissues. Radium-223 is a “calcium mimetic” that, like calcium, accumulates preferentially in areas of bone that are undergoing increased turnover, such as areas where bone metastases are forming. The alpha particle radiation causes double-strand breaks in DNA, killing cells. Radium-223 dichloride (radium-223) is a radioactive isotope that emits low levels of alpha particle radiation. Several drugs have been approved by the Food and Drug Administration (FDA) to prevent pain and fractures in patients with bone metastases, but none of these drugs improves the survival of men with prostate cancer. Bone metastases can cause intense pain, weakness, and bone fractures, greatly impairing quality of life-and in some cases causing death. In most men with metastatic castration-resistant prostate cancer-prostate cancer that no longer responds to hormone therapy-the cancer spreads (metastasizes) to the bones. New England Journal of Medicine ( NEJM), J(See the journal article.) Background Results from a phase III trial called ALSYMPCA show that radium-223 dichloride (Xofigo®) improves overall survival in men with advanced prostate cancer that has spread to their bones compared with a placebo.

Radium facts